Inventurus Knowledge Solutions delivered robust financial performance in the June 2026 quarter, with consolidated net profit rising 27.85% to ₹193.74 crore compared to ₹151.54 crore in the corresponding quarter of the previous year. According to reports from Business Standard, this significant profit growth demonstrates the company's strong operational efficiency and market positioning during the quarter. The healthcare technology company, now known as IKS Health, reported adjusted PAT of ₹215.3 crore, representing a 28% year-on-year growth and highlighting sustained momentum across its business operations.
The company's sales revenue increased 20.74% to ₹893.63 crore in Q1 FY2026, up from ₹740.10 crore in the same period last year. As reported by Business Standard, this revenue growth indicates strong demand for the company's services and effective business expansion strategies during the quarter. In U.S. dollar terms, quarterly revenue increased 12% year-on-year, reflecting healthy business expansion across international markets and supporting the company's global growth strategy. The latest Q1FY27 results show INR revenue rose 21% YoY to ₹8.9 billion with USD revenue up 12% YoY at USD 97 million, meeting analyst estimates.
Operating profit margin (OPM) improved to 32.41% in the June 2026 quarter, compared to 32.12% in the corresponding quarter of the previous year. According to the financial data reported by Business Standard, this margin expansion reflects enhanced operational efficiency and better cost management during the quarter. The company delivered strong financial performance through disciplined cost management, operational efficiency, and capital allocation while continuing to invest in strategic growth initiatives. EBITDA margin was 33.0%, up 24% YoY, though impacted by Trubridge acquisition-related costs, with adjusted margin at ~35% remaining flat quarter-on-quarter and in line with estimates.
Profit before tax (PBT) increased 29% to ₹250.94 crore in Q1 FY2026, compared to ₹194.88 crore in the previous year quarter. Additionally, PBDT (Profit Before Depreciation and Tax) grew 28% to ₹285.23 crore from ₹222.79 crore in the corresponding quarter of the previous year. These figures, as reported by Business Standard, indicate strong operational performance across all profitability metrics and support the company's sustained growth trajectory.
The healthcare technology company continues to expand its Care Enablement Platform, which combines revenue cycle management solutions, clinical documentation support, patient engagement technologies, and operational workflow automation. According to the company, this platform helps hospitals, physician groups, specialty practices, and healthcare systems improve operational efficiency while enhancing patient care delivery. The recently announced TruBridge acquisition represents a significant milestone, expanding IKS Health's capabilities and strengthening its presence among rural and community healthcare providers in the United States. Following its listing on the NSE and BSE in December 2024, IKS Health has continued strengthening its position as a global healthcare technology provider serving major healthcare organizations across the United States. Motilal Oswal maintains a BUY rating with a target price of ₹2,075, expecting a CAGR of 17%/19%/20% in organic revenue/EBITDA/PAT over FY26-28.
